STING agonists, for example, have been employed as immunomodulators in conjunction with mRNA and peptide vaccines.[54, 55] Given its high potency in inducing cellular immunity, PS could be incorporated into many existing or developing vaccine strategies to enhance the CTL response desired in tumor or virus vaccination. This evidence concerns the gene STING1 and neoplasm.